Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 March 2025
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) (TA1024)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 December 2024
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 August 2024
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 August 2024Published: 20 October 2021
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 June 2024
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 April 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 January 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 November 2021
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 June 2021
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC